Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading

To the Editor: The therapeutic potential of antibody-drug conjugates (ADCs) has been recently realized with the approvals of Kadcyla (ado-trastuzumab emtansine)1 and Adcetris (brentuximab vedotin)2. In a seminal paper, Hamblett et al.3 showed that a drug-to-antibody ratio of 4 (DAR4) resulted in an optimal potency and safety profile. The study compared… Download references